Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Oral mSWI/SNF Degrader Reveals PROTAC Resistance Routes
2026-09-25
The study introduces AU-24118, an orally bioavailable degrader of mSWI/SNF components that showed antitumor activity in preclinical prostate cancer models, including enhanced activity with enzalutamide. It also identifies two acquired resistance routes—SMARCA4 bromodomain mutations and ABCB1 overexpression—and reports that the P-glycoprotein inhibitor zosuquidar restored sensitivity to several tested PROTACs in resistant cells.
-
Fluorescein Tyramide for Sensitive Signal Detection
2026-09-25
Fluorescein Tyramide is a green fluorescent labeling dye intended for tyramide signal amplification (TSA) workflows that need to detect low-abundance targets. A mouse study links early-life social deprivation to impaired looming-evoked defensive behavior through oxytocin signaling, but does not establish that Fluorescein Tyramide was used in that research.
-
Podophyllotoxin in Cell-Cycle and Autophagy Research
2026-09-24
Use Podophyllotoxin as a microtubule-directed perturbation to benchmark mitotic arrest, cell viability, and apoptosis in cancer-cell workflows. Pair those assays with autophagic-flux measurements to distinguish a direct drug response from protective autophagy, without assuming results from a different HCC compound apply to Podophyllotoxin.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-24
A 2026 study reports that intravesically delivered lipid nanoparticles carrying chemically modified p21 mRNA can restore tumor-suppressor expression and suppress bladder tumor growth in an orthotopic mouse model. Its findings support localized mRNA delivery as a research strategy while leaving dose optimization, durability, and clinical translation to be established.
-
SGI-1027: DNMT Inhibition and Lysosomal Cell Death
2026-09-23
SGI-1027 is a DNA methyltransferase inhibitor with established epigenetic research applications and a newly reported connection to lysosome-associated cancer cell death. This article explains how to separate methylation-related effects from cytotoxicity when evaluating SGI-1027, including in renal cancer combination studies.
-
PEP, cGAS–STING, and Healthy Aging
2026-09-23
A 2026 Nature Aging study identifies phosphoenolpyruvate (PEP) as an endogenous brake on cGAS-driven inflammation during aging. Its age-dependent trajectory, causal perturbation experiments, and Alzheimer’s disease model findings connect glycolytic metabolism with inflammaging control while also defining important limits for extrapolation to other metabolites such as hexose diphosphate.
-
Fluorescein TSA Fluorescence System Kit Guide
2026-09-22
The Fluorescein TSA Fluorescence System Kit enables localized, high-sensitivity detection of scarce targets in fixed samples. This guide uses diabetic retinal barrier research to explain how tyramide chemistry should influence assay design, controls, imaging, and biological interpretation.
-
Polymyxin B: From Membrane Damage to Assay Design
2026-09-22
Polymyxin B sulfate is more than a membrane-active antibiotic: it is a powerful experimental probe for Gram-negative bacterial infection research and innate immune signaling. This guide connects its mechanism with dendritic cell assays, bacteremia models, and microbiome-aware study design.
-
Fluorescein TSA Fluorescence System Kit Guide
2026-09-21
Learn how to apply tyramide-based fluorescence amplification to difficult IHC, ICC, and ISH targets without sacrificing spatial context. This practical guide connects the kit to proximity-based spatial proteomics, with workflow parameters, assay controls, and troubleshooting strategies for low-abundance biomolecule detection.
-
D-N-Acetylgalactosamine: Protocol and QC Guide
2026-09-21
D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for glycoprotein and brain heteropolysaccharide workflows where solvent compatibility and controlled storage are important. It is suitable for aqueous or validated DMSO preparations, but not for ethanol-based protocols or long-term storage of prepared solutions.
-
α-Bungarotoxin: Nicotinic Receptor Blockade
2026-09-20
α-Bungarotoxin is a high-affinity α7 nicotinic acetylcholine receptor antagonist used to study nicotinic receptor blockade and cholinergic signaling. In a rat placental ischemia model, α-bungarotoxin removed pyridostigmine-associated effects, supporting α7 receptor involvement without demonstrating clinical efficacy.
-
Cy3-UTP for Nuclear Speckle RNA Mapping
2026-09-19
Cy3-UTP enables a structure-aware approach to fluorescent RNA experiments inspired by new findings on Alu-containing RNAs and nuclear speckles. This guide connects in vitro transcription RNA labeling with mechanistic controls for RNA organization, RNA-protein binding, and fluorescence imaging of RNA.
-
Syringin Enhances Sunitinib in Renal Cell Carcinoma
2026-09-18
A 2024 Journal of Functional Foods study identifies syringin as a natural-product candidate that suppresses renal cell carcinoma behavior and increases cellular sensitivity to sunitinib. By combining network pharmacology, molecular docking, cell-based assays, and pathway analysis, the work connects these effects to EGFR/PI3K/Akt signaling while highlighting important limits for translation beyond in vitro research.
-
Hesperadin for Reliable Mitotic Assays
2026-09-18
This scenario-based guide explains how Hesperadin (SKU A4118) can serve as a mechanistic Aurora B kinase inhibitor control in proliferation, cytotoxicity, and cell-cycle assays. It connects biochemical potency, mitotic phenotypes, stock preparation, and vendor-selection considerations to more interpretable laboratory data.
-
Patient-Derived Colorectal Organoids: A Practical Guide
2026-09-17
This 2025 protocol paper presents a standardized workflow for generating patient-derived colorectal organoids from normal crypts, polyps, and tumors. Its practical contribution is the integration of tissue processing, crypt isolation, culture establishment, apical-out conversion, immunofluorescence characterization, quality control, and troubleshooting for translational research.